Induced nuclear reactions: processes – systems – and elements – Nuclear transmutation – By neutron bombardment
Reexamination Certificate
2000-03-29
2002-09-24
Behrend, Harvey E. (Department: 3641)
Induced nuclear reactions: processes, systems, and elements
Nuclear transmutation
By neutron bombardment
C376S311000, C376S314000, C376S358000, C250S4320PD
Reexamination Certificate
active
06456680
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is in the field of radioisotope production and in particular relates to a method of producing strontium-89.
2. Description of the Prior Art
Radioisotopes have been used in nuclear medicine for diagnostics and therapeutics for more than fifty years. Medical radioisotope production is an important industry using more than 50% of the radioisotopes produced in the world. More than 160 radioisotopes of 80 chemical elements are produced with the help of nuclear reactors and charged particle accelerators today.
One of the most effective modern therapeutic radioisotopes is strontium-89. It is used for pain palliation instead of drugs when treating cancer. When medicine containing strontium-89 is introduced into an organism, it is absorbed and distributed in the bone metastases providing for a long anesthetic effect.
Strontium-89 radioisotope has a half-life of 52.7 days with &bgr; decay (decays to Y
89
, a stable isotope). The maximum energy of the &bgr;-particles is 1463 keV. The attendant y-radiation energy is 909.1 keV.
Strontium is a biochemical analog of calcium that has the same transport mechanism in the human body. Strontium chloride SrCl
2
introduced to the vein is mainly accumulated in bone metastases providing for a long anesthetic effect so it is not necessary to take drugs frequently and the patient does not become tolerant of them. Malignant tumors tending to metastases in the skeleton are: mammary gland, large intestine, thyroid gland, prostate, kidney, and skin cancer. The maximum range of &bgr;-particles of strontium-89 in the bone does not exceed 7 mm, so its radiation effects are isolated to the small area of the skeleton and its radiation burden on the marrow and nearby soft tissue is not significant. As strontium-89 is incorporated in the mineral structure of the bone, diseased metabolism does not take place, and it remains there for more than 100 days. Healthy bone contains a small component of the injected dose and loses it quickly during the first fortnight. One injection of strontium chloride is about 4 mCi and is effective for 3 to 6 months. Clinical tests of the preparation based on
89
SrCl
3
showed that 65-76% of the patients said that pain had been reduced significantly, and there was full anaesthetic effect in 20% of the cases. In addition, doctors think that strontium-89 chloride has a therapeutic effect, which means it does not only block metastases but also reduces them.
One reactor method of strontium-89 production consists of irradiating a target of strontium carbonate SrCO
3
with neutrons having a thermal neutron spectrum. A target made from metallic strontium is irradiated by the neutron flux of a nuclear reactor. Natural strontium consists of the following isotopes: Sr
84
at 0.56%, Sr
86
at 9.9%, Sr
87
at 7.0% and Sr
88
at 82.6%. The strontium-89 radioisotope is formed in the target as a result of the neutron capture reaction of one of the strontium isotopes Sr
88
(n,y) Sr
89
. A highly enriched target containing Sr
88
>99.9% is used because it is necessary to eliminate strontium-85 from the reaction Sr
84
(n,y) Sr
85
, an undesirable admixture. This is a convenient production method and takes place in a normal research reactor. The cross-section of the (n,y)-reaction is only 6×10
−27
cm
2
, however, which restricts the productivity of this method.
Another strontium-89 production method is based the threshold reaction of neutron capture with the emission of a charged particle Y
89
(n,p) Sr
89
. A target containing natural monoisotope Yttrium-89 is irradiated in the neutron flux of a nuclear reactor with a fast neutron spectrum and is subsequently subjected to radiochemical reprocessing for extraction. Strontium-89 production can achieve about 10-15 mCi per gram of yttrium in optimum conditions. The target is a pellet of yttrium oxide Y
2
O
3
of high purity that is pressed and annealed at 1600° C. This method produces almost no radioactive wastes and the end-product does not contain harmful admixtures, e.g., the quantity of attendant strontium-90 is less than 2×10
−4
atomic percent.
This method has an extremely low productivity due to the small cross-section of the (n,p)-reaction on Y
89
, less than 0.3×10
−27
cm
2
for neutrons of the fission spectrum. It can only occur in reactors with a fast neutron spectrum, and there are few in existence. In addition, yttrium purified without admixtures of uranium should be used (the uranium content in the Y
2
O
3
pellets must not exceed 10
−5
by mass). Low productivity and the need for reactors with a fast neutron spectrum are the main problems with this method.
There is clearly a need for a more efficient method for the production of strontium-89, particularly one that uses a relatively low power reactor.
SUMMARY OF THE INVENTION
A solution nuclear reactor containing a uranyl sulfate fuel solution produces krypton-89 during operation. Krypton-89 is in the form of a gas that bubbles to the surface of the fuel solution and occupies the enclosed volume above the fuel. An inert gas transports the krypton-89, along with other radioisotope fragments, in a sealed system to a trap area where any accompanying relatively short half-life krypton-90 is allowed to decay to strontium-90. The strontium-90 is removed. Then the krypton-89 is transported to a catching system where it remains until it fully decays to strontium-89. The strontium-89 is removed from the inert gas with the help of sorption in a carbon trap or by chemical interaction in an acid environment. The inert gas is returned to the reactor core.
REFERENCES:
patent: 2815321 (1957-12-01), Wigner, II et al.
patent: 2860093 (1958-11-01), Wigner, I et al.
patent: 2945794 (1960-07-01), Winters et al.
patent: 3074776 (1963-01-01), Ryan et al.
patent: 3080307 (1963-03-01), Rinald
patent: 3154473 (1964-10-01), Martin, II
patent: 3166478 (1965-01-01), Lindstrom
patent: 3217471 (1965-11-01), Silverman
patent: 3284305 (1966-11-01), Urey et al.
patent: 3791107 (1974-02-01), Gustavsson
patent: 3803802 (1974-04-01), Schroter et al.
patent: 3871841 (1975-03-01), Queiser et al.
patent: 3944646 (1976-03-01), Martin, I
patent: 4012490 (1977-03-01), Lofredo
patent: 4532102 (1985-07-01), Cawley
patent: 5596611 (1997-01-01), Ball, I
patent: 5875220 (1999-02-01), Zhuikov et al.
Hitachi Review, vol. 23, No. 1, pp 2-7, Saito et al, 1974.*
Appl. Radiat. Isot., vol. 40, No. 4, pp 315-324, Cheng et al, 1989.*
Nuclear Sci. and Eng., vol. 13, pp 297-298, Townley et al. (I), Jul. 1962.*
Nuclear Sci. and Eng., vol. 10, pp 346-351, Townley et al (II), 1961.*
Federal Document Clearing House Congressional Testimony, by Ball (II), Dec. 6, 1993.
Abalin S. S.
Chuvilin D. Yu.
Grogoriev G. Y.
Khvostionov V. E.
Pavshook V. A.
Becker R W
Behrend Harvey E.
R W Becker & Associates
TCI Incorporated
LandOfFree
Method of strontium-89 radioisotope production does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of strontium-89 radioisotope production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of strontium-89 radioisotope production will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2873347